DIEBOLD NIXDORF INC (DBD) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:DBD - US2536512021 - Common Stock
67.65 USD
+0.54 (+0.8%)
67.65 USD
0 (0%)
Overall DBD gets a fundamental rating of 4 out of 10. We evaluated DBD against 35 industry peers in the Technology Hardware, Storage & Peripherals industry. DBD has an average financial health and profitability rating. DBD has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
DBD had positive earnings in the past year.
In the past year DBD had a positive cash flow from operations.
In the past 5 years DBD reported 4 times negative net income.
In multiple years DBD reported negative operating cash flow during the last 5 years.
1.2 Ratios
The Return On Assets of DBD (1.36%) is better than 62.86% of its industry peers.
DBD has a better Return On Equity (4.57%) than 74.29% of its industry peers.
DBD has a Return On Invested Capital of 8.85%. This is in the better half of the industry: DBD outperforms 71.43% of its industry peers.
The Average Return On Invested Capital over the past 3 years for DBD is significantly below the industry average of 15.26%.
The last Return On Invested Capital (8.85%) for DBD is above the 3 year average (5.12%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.36% | ||
| ROE | 4.57% | ||
| ROIC | 8.85% |
ROA(3y)4.54%
ROA(5y)0.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)5.12%
ROIC(5y)5.58%
1.3 Margins
With a decent Profit Margin value of 1.37%, DBD is doing good in the industry, outperforming 62.86% of the companies in the same industry.
The Operating Margin of DBD (7.47%) is better than 77.14% of its industry peers.
DBD's Operating Margin has improved in the last couple of years.
DBD has a worse Gross Margin (25.48%) than 60.00% of its industry peers.
In the last couple of years the Gross Margin of DBD has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7.47% | ||
| PM (TTM) | 1.37% | ||
| GM | 25.48% |
OM growth 3Y20.78%
OM growth 5Y40.66%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.32%
GM growth 5Y0.68%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so DBD is destroying value.
Compared to 1 year ago, DBD has about the same amount of shares outstanding.
DBD has less shares outstanding than it did 5 years ago.
DBD has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 1.96 indicates that DBD is not a great score, but indicates only limited risk for bankruptcy at the moment.
DBD has a Altman-Z score of 1.96. This is comparable to the rest of the industry: DBD outperforms 51.43% of its industry peers.
DBD has a debt to FCF ratio of 3.71. This is a good value and a sign of high solvency as DBD would need 3.71 years to pay back of all of its debts.
With a decent Debt to FCF ratio value of 3.71, DBD is doing good in the industry, outperforming 68.57% of the companies in the same industry.
A Debt/Equity ratio of 0.84 indicates that DBD is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.84, DBD is doing worse than 60.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.84 | ||
| Debt/FCF | 3.71 | ||
| Altman-Z | 1.96 |
ROIC/WACC0.94
WACC9.37%
2.3 Liquidity
A Current Ratio of 1.36 indicates that DBD should not have too much problems paying its short term obligations.
DBD has a Current ratio (1.36) which is in line with its industry peers.
DBD has a Quick Ratio of 1.36. This is a bad value and indicates that DBD is not financially healthy enough and could expect problems in meeting its short term obligations.
DBD has a Quick ratio of 0.89. This is comparable to the rest of the industry: DBD outperforms 54.29% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.36 | ||
| Quick Ratio | 0.89 |
3. Growth
3.1 Past
The earnings per share for DBD have decreased strongly by -38.07% in the last year.
DBD shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 69.69% yearly.
The Revenue has decreased by -2.86% in the past year.
DBD shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -3.18% yearly.
EPS 1Y (TTM)-38.07%
EPS 3Y69.69%
EPS 5YN/A
EPS Q2Q%150.91%
Revenue 1Y (TTM)-2.86%
Revenue growth 3Y-1.33%
Revenue growth 5Y-3.18%
Sales Q2Q%1.95%
3.2 Future
DBD is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 19.21% yearly.
DBD is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.51% yearly.
EPS Next Y8.85%
EPS Next 2Y12.85%
EPS Next 3Y19.21%
EPS Next 5YN/A
Revenue Next Year1.72%
Revenue Next 2Y1.93%
Revenue Next 3Y2.51%
Revenue Next 5YN/A
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 18.48 indicates a rather expensive valuation of DBD.
77.14% of the companies in the same industry are more expensive than DBD, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of DBD to the average of the S&P500 Index (26.76), we can say DBD is valued slightly cheaper.
A Price/Forward Earnings ratio of 13.76 indicates a correct valuation of DBD.
Compared to the rest of the industry, the Price/Forward Earnings ratio of DBD indicates a somewhat cheap valuation: DBD is cheaper than 62.86% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of DBD to the average of the S&P500 Index (23.96), we can say DBD is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.48 | ||
| Fwd PE | 13.76 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of DBD indicates a rather cheap valuation: DBD is cheaper than 94.29% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, DBD is valued cheaper than 82.86% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 9.64 | ||
| EV/EBITDA | 7.5 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates DBD does not grow enough to justify the current Price/Earnings ratio.
A more expensive valuation may be justified as DBD's earnings are expected to grow with 19.21% in the coming years.
PEG (NY)2.09
PEG (5Y)N/A
EPS Next 2Y12.85%
EPS Next 3Y19.21%
5. Dividend
5.1 Amount
No dividends for DBD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
67.65
+0.54 (+0.8%)
Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupTechnology Hardware & Equipment
GICS IndustryTechnology Hardware, Storage & Peripherals
Earnings (Last)
Earnings (Next)
Inst Owners105.36%
Inst Owner Change-2.66%
Ins Owners1.82%
Ins Owner Change0%
Market Cap2.43B
Revenue(TTM)3.69B
Net Income(TTM)50.60M
Analysts82.86
Price Target80.58 (19.11%)
Short Float %2.16%
Short Ratio4.21
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)52.97%
Min EPS beat(2)46.39%
Max EPS beat(2)59.55%
EPS beat(4)3
Avg EPS beat(4)24.69%
Min EPS beat(4)-8.92%
Max EPS beat(4)59.55%
EPS beat(8)6
Avg EPS beat(8)71.52%
EPS beat(12)8
Avg EPS beat(12)-72.18%
EPS beat(16)9
Avg EPS beat(16)-86.09%
Revenue beat(2)1
Avg Revenue beat(2)1.41%
Min Revenue beat(2)-0.2%
Max Revenue beat(2)3.02%
Revenue beat(4)1
Avg Revenue beat(4)0.15%
Min Revenue beat(4)-1.34%
Max Revenue beat(4)3.02%
Revenue beat(8)4
Avg Revenue beat(8)0.31%
Revenue beat(12)4
Avg Revenue beat(12)-0.58%
Revenue beat(16)4
Avg Revenue beat(16)-1.83%
PT rev (1m)4.41%
PT rev (3m)4.41%
EPS NQ rev (1m)0.83%
EPS NQ rev (3m)11.47%
EPS NY rev (1m)13.35%
EPS NY rev (3m)20.23%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.09%
Revenue NY rev (1m)-0.36%
Revenue NY rev (3m)-0.36%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.48 | ||
| Fwd PE | 13.76 | ||
| P/S | 0.66 | ||
| P/FCF | 9.64 | ||
| P/OCF | 8.69 | ||
| P/B | 2.19 | ||
| P/tB | N/A | ||
| EV/EBITDA | 7.5 |
EPS(TTM)3.66
EY5.41%
EPS(NY)4.92
Fwd EY7.27%
FCF(TTM)7.01
FCFY10.37%
OCF(TTM)7.79
OCFY11.51%
SpS102.88
BVpS30.87
TBVpS-9.56
PEG (NY)2.09
PEG (5Y)N/A
Graham Number50.42
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.36% | ||
| ROE | 4.57% | ||
| ROCE | 11.2% | ||
| ROIC | 8.85% | ||
| ROICexc | 9.91% | ||
| ROICexgc | 29.15% | ||
| OM | 7.47% | ||
| PM (TTM) | 1.37% | ||
| GM | 25.48% | ||
| FCFM | 6.82% |
ROA(3y)4.54%
ROA(5y)0.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)5.12%
ROIC(5y)5.58%
ROICexc(3y)6.13%
ROICexc(5y)6.88%
ROICexgc(3y)21.8%
ROICexgc(5y)29.05%
ROCE(3y)6.48%
ROCE(5y)7.06%
ROICexgc growth 3Y-11.73%
ROICexgc growth 5Y37.89%
ROICexc growth 3Y4.77%
ROICexc growth 5Y35.34%
OM growth 3Y20.78%
OM growth 5Y40.66%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.32%
GM growth 5Y0.68%
F-Score7
Asset Turnover0.99
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.84 | ||
| Debt/FCF | 3.71 | ||
| Debt/EBITDA | 2.28 | ||
| Cap/Depr | 20.59% | ||
| Cap/Sales | 0.75% | ||
| Interest Coverage | 2.89 | ||
| Cash Conversion | 68.06% | ||
| Profit Quality | 497.23% | ||
| Current Ratio | 1.36 | ||
| Quick Ratio | 0.89 | ||
| Altman-Z | 1.96 |
F-Score7
WACC9.37%
ROIC/WACC0.94
Cap/Depr(3y)16.93%
Cap/Depr(5y)15.92%
Cap/Sales(3y)0.61%
Cap/Sales(5y)0.61%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-38.07%
EPS 3Y69.69%
EPS 5YN/A
EPS Q2Q%150.91%
EPS Next Y8.85%
EPS Next 2Y12.85%
EPS Next 3Y19.21%
EPS Next 5YN/A
Revenue 1Y (TTM)-2.86%
Revenue growth 3Y-1.33%
Revenue growth 5Y-3.18%
Sales Q2Q%1.95%
Revenue Next Year1.72%
Revenue Next 2Y1.93%
Revenue Next 3Y2.51%
Revenue Next 5YN/A
EBIT growth 1Y-5.55%
EBIT growth 3Y19.17%
EBIT growth 5Y36.19%
EBIT Next Year24.55%
EBIT Next 3Y14.01%
EBIT Next 5YN/A
FCF growth 1Y171.3%
FCF growth 3Y8.67%
FCF growth 5Y113.09%
OCF growth 1Y186.31%
OCF growth 3Y6.68%
OCF growth 5Y26.59%
DIEBOLD NIXDORF INC / DBD FAQ
What is the fundamental rating for DBD stock?
ChartMill assigns a fundamental rating of 4 / 10 to DBD.
What is the valuation status for DBD stock?
ChartMill assigns a valuation rating of 5 / 10 to DIEBOLD NIXDORF INC (DBD). This can be considered as Fairly Valued.
What is the profitability of DBD stock?
DIEBOLD NIXDORF INC (DBD) has a profitability rating of 5 / 10.
How financially healthy is DIEBOLD NIXDORF INC?
The financial health rating of DIEBOLD NIXDORF INC (DBD) is 4 / 10.
Can you provide the dividend sustainability for DBD stock?
The dividend rating of DIEBOLD NIXDORF INC (DBD) is 0 / 10 and the dividend payout ratio is 0%.